bioAffinity Technologies, Inc. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value
bioAffinity Technologies, Inc. (BIAF) had Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value of $11.15 million as of 2021-12-31, per its 10-K filed 2023-03-31.
Discontinued › Notes › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue · last filed 2023-03-31
- 2021-12-31: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $11.15M.
- 2020-12-31: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $9.77M.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value |
|---|---|
| 2021-12-31 | $11.15M 10-K · filed 2023-03-31 |
| 2020-12-31 | $9.77M 10-K · filed 2023-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |